255 related articles for article (PubMed ID: 24575976)
1. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
5. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
6. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
[TBL] [Abstract][Full Text] [Related]
7. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of miR-210 involved in epithelial-mesenchymal transition of pancreatic cancer cells under hypoxia.
Ni J; Zhou S; Yuan W; Cen F; Yan Q
J Recept Signal Transduct Res; 2019; 39(5-6):399-406. PubMed ID: 31875764
[No Abstract] [Full Text] [Related]
9. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
[TBL] [Abstract][Full Text] [Related]
10. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
[TBL] [Abstract][Full Text] [Related]
12. Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.
Tsukasa K; Ding Q; Yoshimitsu M; Miyazaki Y; Matsubara S; Takao S
Hum Cell; 2015 Oct; 28(4):167-74. PubMed ID: 25997702
[TBL] [Abstract][Full Text] [Related]
13. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Zhao T; Jin F; Xiao D; Wang H; Huang C; Wang X; Gao S; Liu J; Yang S; Hao J
Theranostics; 2020; 10(9):4088-4100. PubMed ID: 32226541
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line.
Imaizumi A; Onishi H; Yamasaki A; Kawamoto M; Umebayashi M; Morisaki T; Hasumi K
Anticancer Res; 2016 Feb; 36(2):653-7. PubMed ID: 26851020
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of gemcitabine-resistant pancreatic tumor cells.
Shah AN; Summy JM; Zhang J; Park SI; Parikh NU; Gallick GE
Ann Surg Oncol; 2007 Dec; 14(12):3629-37. PubMed ID: 17909916
[TBL] [Abstract][Full Text] [Related]
17. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
18. Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells.
Cheng ZX; Wang DW; Liu T; Liu WX; Xia WB; Xu J; Zhang YH; Qu YK; Guo LQ; Ding L; Hou J; Zhong ZH
Oncol Rep; 2014 Apr; 31(4):1891-8. PubMed ID: 24535079
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
